Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

Clinical trial NCT06700798 · RECRUITING

Trial details

NCT number: NCT06700798
Sponsor: Fei Li
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Marginal Zone Lymphoma(MZL)

Start date: 2024-12-01
Primary completion: 2026-05-04
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.